{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:47:43Z","timestamp":1787168863297,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12325-022-02104-6","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T13:04:35Z","timestamp":1647435875000},"page":"2109-2127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct03801928","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Bincy","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertus","family":"Eksteen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan","family":"Nedd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishikesh","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shelbaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Soonasra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"2104_CR1","doi-asserted-by":"publisher","first-page":"204062231989929","DOI":"10.1177\/2040622319899297","volume":"11","author":"K Hazel","year":"2020","unstructured":"Hazel K, O\u2019Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020;11:2040622319899297.","journal-title":"Ther Adv Chronic Dis"},{"issue":"9317","key":"2104_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet"},{"issue":"23","key":"2104_CR3","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376.","journal-title":"N Engl J Med"},{"issue":"9","key":"2104_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350(9):876\u201385.","journal-title":"N Engl J Med"},{"issue":"10","key":"2104_CR5","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","volume":"2","author":"BE Sands","year":"2004","unstructured":"Sands BE, et al. Long-term treatment of rectovaginal fistulas in Crohn\u2019s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004;2(10):912\u201320.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2104_CR6","doi-asserted-by":"crossref","first-page":"175628481985805","DOI":"10.1177\/1756284819858052","volume":"12","author":"MFG Veloz","year":"2019","unstructured":"Veloz MFG, et al. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Ther Adv Gastroenterol. 2019;12:1756284819858052\u20131756284819858052.","journal-title":"Ther Adv Gastroenterol"},{"issue":"8","key":"2104_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/acr2.11067","volume":"1","author":"S Kapoor","year":"2019","unstructured":"Kapoor S, et al. Real-life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: the adalimumab biosimilar patient registry data. ACR Open Rheumatol. 2019;1(8):480\u20134.","journal-title":"ACR Open Rheumatol"},{"key":"2104_CR8","unstructured":"FDA approves Inflectra, a biosimilar to Remicade. 2016.https:\/\/www.drugs.com\/newdrugs\/fda-approves-inflectra-infliximab-dyyb-biosimilar-remicade-4364.html."},{"key":"2104_CR9","doi-asserted-by":"publisher","unstructured":"Mart\u00edn-Guti\u00e9rrez N, S\u00e1nchez-Hern\u00e1ndez JG, Rebollo N, Pordomingo AF, Mu\u00f1oz F, Otero MJ. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease [published online ahead of print, 2020 Oct 28]. Eur J Hosp Pharm. 2020. https:\/\/doi.org\/10.1136\/ejhpharm-2020-002410.","DOI":"10.1136\/ejhpharm-2020-002410"},{"issue":"8","key":"2104_CR10","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1111\/jgh.15399","volume":"36","author":"S Sagami","year":"2021","unstructured":"Sagami S, et al. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. J Gastroenterol Hepatol. 2021;36(8):2091\u2013100.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"2104_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1517\/14712598.2015.1064893","volume":"15","author":"K Farkas","year":"2015","unstructured":"Farkas K, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn\u2019s disease and ulcerative colitis\u2014experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257\u201362.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"2104_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","volume":"10","author":"KB Gecse","year":"2016","unstructured":"Gecse KB, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, Nationwide Cohort. J Crohns Colitis. 2016;10(2):133\u201340.","journal-title":"J Crohns Colitis"},{"issue":"12","key":"2104_CR13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/jgh.12997","volume":"30","author":"YS Jung","year":"2015","unstructured":"Jung YS, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705\u201312.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2104_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10620-014-3392-z","volume":"60","author":"YS Kang","year":"2015","unstructured":"Kang YS, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60(4):951\u20136.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"2104_CR15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1517\/14712598.2015.1103733","volume":"15","author":"E Nikiphorou","year":"2015","unstructured":"Nikiphorou E, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677\u201383.","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"2104_CR16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/ecco-jcc\/jjw087","volume":"10","author":"LJ Smits","year":"2016","unstructured":"Smits LJ, et al. Clinical outcomes following a switch from Remicade\u00ae to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10(11):1287\u201393.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2104_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","volume":"27","author":"Y Tanaka","year":"2017","unstructured":"Tanaka Y, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27(2):237\u201345.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"2104_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/pds.4809","volume":"29","author":"RJ Desai","year":"2020","unstructured":"Desai RJ, Kim SC, Curtis JR, et al. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiol Drug Saf. 2020;29(7):757\u2013769.https:\/\/doi.org\/10.1002\/pds.4809.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"2104_CR19","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/apt.13990","volume":"45","author":"Y Komaki","year":"2017","unstructured":"Komaki Y, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-\u03b1 agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043\u201357.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2104_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/00365521.2018.1464203","volume":"53","author":"R Ratnakumaran","year":"2018","unstructured":"Ratnakumaran R, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol. 2018;53(6):700\u20137.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"2104_CR21","first-page":"169","volume":"12","author":"M Kaniewska","year":"2017","unstructured":"Kaniewska M, Moniuszko A, Rydzewska G. The efficacy and safety of the biosimilar product (Inflectra(\u00ae)) compared to the reference drug (Remicade(\u00ae)) in rescue therapy in adult patients with ulcerative colitis. Prz Gastroenterol. 2017;12(3):169\u201374.","journal-title":"Prz Gastroenterol"},{"issue":"6","key":"2104_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/00365521.2018.1463391","volume":"53","author":"ML H\u00f8ivik","year":"2018","unstructured":"H\u00f8ivik ML, et al. Switching from originator to biosimilar infliximab\u2014real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018;53(6):692\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"2104_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.17235\/reed.2018.5368\/2017","volume":"110","author":"MFG Veloz","year":"2018","unstructured":"Veloz MFG, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. Rev Esp Enferm Dig. 2018;110(9):564\u201370.","journal-title":"Rev Esp Enferm Dig"},{"issue":"3","key":"2104_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/ibd\/izy264","volume":"25","author":"A Armuzzi","year":"2019","unstructured":"Armuzzi A, et al. The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis. 2019;25(3):568\u201379.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2104_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7326\/M18-1512","volume":"170","author":"A Meyer","year":"2019","unstructured":"Meyer A, et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: A French Equivalence Study. Ann Intern Med. 2019;170(2):99\u2013107.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2104_CR26","first-page":"628","volume":"26","author":"M Bronswijk","year":"2020","unstructured":"Bronswijk M, et al. Evaluating efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar CT-P13: experience from a large tertiary referral center. Inflamm Bowel Dis. 2020;26(4):628\u201334.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2104_CR27","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00384-019-03354-7","volume":"34","author":"MA Ebada","year":"2019","unstructured":"Ebada MA, et al. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. Int J Colorectal Dis. 2019;34(10):1633\u201352.","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"2104_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/21556660.2019.1626735","volume":"8","author":"C Gheorghe","year":"2019","unstructured":"Gheorghe C, Svoboda P, Mateescu B. Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn\u2019s disease or ulcerative colitis. J Drug Assess. 2019;8(1):129\u201334.","journal-title":"J Drug Assess"},{"issue":"46","key":"2104_CR29","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.3748\/wjg.v24.i46.5288","volume":"24","author":"MF Guerra Veloz","year":"2018","unstructured":"Guerra Veloz MF, et al. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol. 2018;24(46):5288\u201396.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2104_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40259-020-00409-y","volume":"34","author":"SL Ho","year":"2020","unstructured":"Ho SL, et al. Effectiveness of switching from reference product Infliximab to Infliximab-Dyyb in patients with inflammatory bowel disease in an integrated healthcare system in the United States: a retrospective, propensity score-matched, non-inferiority cohort study. BioDrugs. 2020;34(3):395\u2013404.","journal-title":"BioDrugs"},{"issue":"12","key":"2104_CR31","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.cgh.2018.12.036","volume":"17","author":"A Ilias","year":"2019","unstructured":"Ilias A, et al. Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to remicade. Clin Gastroenterol Hepatol. 2019;17(12):2506-2513.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10086","key":"2104_CR32","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316.","journal-title":"Lancet"},{"issue":"9","key":"2104_CR33","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/jgh.14645","volume":"34","author":"NH Kim","year":"2019","unstructured":"Kim NH, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2019;34(9):1523\u201332.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2104_CR34","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5217\/ir.2019.00030","volume":"17","author":"T Nakagawa","year":"2019","unstructured":"Nakagawa T, et al. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 2019;17(4):504\u201315.","journal-title":"Intest Res"},{"issue":"12","key":"2104_CR35","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.dld.2019.08.020","volume":"51","author":"N Petitdidier","year":"2019","unstructured":"Petitdidier N, et al. Patients\u2019 perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Dig Liver Dis. 2019;51(12):1652\u201360.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2104_CR36","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1007\/s10620-018-5406-8","volume":"64","author":"N Plevris","year":"2019","unstructured":"Plevris N, et al. Implementation of CT-P13 via a managed switch programme in Crohn\u2019s disease: 12-month real-world outcomes. Dig Dis Sci. 2019;64(6):1660\u20137.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"2104_CR37","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S2468-1253(18)30082-7","volume":"3","author":"AS Strik","year":"2018","unstructured":"Strik AS, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018;3(6):404\u201312.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2104_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/FTD.0000000000000601","volume":"41","author":"K van Hoeve","year":"2019","unstructured":"van Hoeve K, et al. Efficacy, pharmacokinetics, and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease. Ther Drug Monit. 2019;41(3):317\u201324.","journal-title":"Ther Drug Monit"},{"issue":"10182","key":"2104_CR39","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","volume":"393","author":"BD Ye","year":"2019","unstructured":"Ye BD, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699\u2013707.","journal-title":"Lancet"},{"issue":"11","key":"2104_CR40","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/ecco-jcc\/jjz070","volume":"13","author":"M Chaparro","year":"2019","unstructured":"Chaparro M, et al. Effectiveness and safety of the switch from Remicade\u00ae to CT-P13 in patients with inflammatory bowel disease. J Crohns Colitis. 2019;13(11):1380\u20136.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2104_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ibd.21697","volume":"18","author":"W Reinisch","year":"2012","unstructured":"Reinisch W, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and-2 extension studies. Inflamm Bowel Dis. 2012;18(2):201\u201311.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2104_CR42","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/apt.12145","volume":"37","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37(2):204\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2104_CR43","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","volume":"56","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease. Gut. 2007;56(9):1226\u201331.","journal-title":"Gut"},{"issue":"9","key":"2104_CR44","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/ibd.21928","volume":"18","author":"K Yoshida","year":"2012","unstructured":"Yoshida K, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn\u2019s disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2012;18(9):1617\u201323.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02104-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02104-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02104-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T04:22:00Z","timestamp":1651292520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02104-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2104"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02104-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}